Ligand Pharmaceuticals Incorporated Share Price & Technical Analysis
LGND · $233.2 (+1.69%)
Healthcare / Biotechnology
$233.2
+1.69%
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI for the treatment of immunoglobulin a nephropathy; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight…
Price chart
Seasonality
May has 1 positive and 4 negative years (last 5 years shown)
0% return in May, 2% avg return in past 3 year May month.
19% return in 2026, 41% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 2% | 3% | 1% | 13% | 0% | – | – | – | – | – | – | – | 19% |
| 25 | 8% | 7% | -16% | 5% | -8% | 11% | 17% | 23% | 10% | 8% | 5% | -5% | 65% |
| 24 | 2% | 8% | -9% | -5% | 21% | -1% | 30% | -2% | -5% | 6% | 13% | -12% | 47% |
| 23 | 3% | 3% | 2% | 4% | -7% | 3% | -7% | -1% | -10% | -13% | 11% | 23% | 11% |
| 22 | -19% | -19% | 12% | -19% | -4% | 0% | 4% | 1% | -6% | 2% | 33% | -8% | -24% |
Monthly return % by calendar month · historical pattern, not a forecast
Neutral · Strong · Uptrend
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI for the treatment of immunoglobulin a nephropathy; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma. The company also provides Teriparatide injection product for osteoporosis; RYLAZE, a recombinant erwinia asparaginase for acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes in adults and children aged 8 years and older with Stage 2 T1D; and VAXNEUVANCE for the prevention of invasive disease caused by streptococcus pneumoniae serotypes. In addition, it offers Duavee for menopause; Frovatriptan to treat Neurology; FYCOMPA and SESQUIENT for CNS; MEKINIST for cardiology; Nexterone, a captisol-enabled formulation of amiodarone; VEKLURY, an antiviral treatment for COVID-19; and Viviant for osteoporosis. Further, the company develops ACLX-002, Ciforadenant, UGN-301, Viright, MB07133, BOT/BAL, and Lasofoxifene for oncology; Ensifentrine for respiratory disease; QTORIN for rare disease; Sparsentan for kidney disease; VK2809 for hepatology; ANEB-001 for acute cannabinoid intoxication; Reproxalap for opthamology; VK0214 for Rare Disease; and VK5211 for musculoskeletal disorder. The company was incorporated in 1987 and is based in Jupiter, Florida.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$4.37B
P/E ratio
28.4
52W high
$247.4
52W low
$98.89
Volume
1,34,028
Beta
1.07
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Ligand Pharmaceuticals Incorporated share price today?
- Ligand Pharmaceuticals Incorporated (LGND) last traded around $233.2 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does LGND have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for LGND. Download the app for real-time alerts.
- How can I analyze Ligand Pharmaceuticals Incorporated stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.